Infection with hepatitis B and C virus in Europe: A systematic review of prevalence and cost-effectiveness of screening

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Hahné, Susan J M ^a   Veldhuijzen, Irene K ^b   Wiessing, Lucas ^d   Lim, Tek Ang ^c   Salminen, Mika ^c   Laar, Marita van de ^c  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b Public Health Service of the Rotterdam Region   (Netherlands)

^c EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^d EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION   (Portugal)

Author keywords

Anti HCV Ab; Cost effectiveness analyses; Europe; HBsAg; Hepatitis B virus; Hepatitis C virus; Prevalence

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY;

ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN DETECTION; ARTICLE; BLOOD DONOR; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; EUROPE; HEALTH CARE COST; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HUMAN; IMMIGRANT; INTRAVENOUS DRUG ABUSE; MASS SCREENING; MEN WHO HAVE SEX WITH MEN; PEER REVIEW; PREGNANT WOMAN; PRENATAL DIAGNOSIS; PREVALENCE; PRISONER; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; SCREENING TEST; SEROPREVALENCE; SYSTEMATIC REVIEW; VIRUS TRANSMISSION;

ADULT; COST-BENEFIT ANALYSIS; EUROPE; FEMALE; HEPATITIS B; HEPATITIS C; HOMOSEXUALITY, MALE; HUMANS; MALE; PREVALENCE; SUBSTANCE ABUSE, INTRAVENOUS; TRANSIENTS AND MIGRANTS;

EID: 84876190039     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-181     Document Type: Article

References (169)

1. Lok AS. Chronic hepatitis B. N Engl J Med 2002, 346:1682-1683. 10.1056/NEJM200205303462202, 12037146.
2. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002, 36:S35-S46.
3. Medley GF, Lindop NA, Edmunds WJ, Nokes DJ. Hepatitis-B virus endemicity: heterogeneity, catastrophic dynamics and control. Nat Med 2001, 7:619-624. 10.1038/87953, 11329065.
4. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008, 359:1486-1500. 10.1056/NEJMra0801644, 18832247.
5. World Health Organization Hepatitis B 2008, http://www.who.int/mediacentre/factsheets/fs204/en/, World Health Organization.
6. World Health Organization Hepatitis C 2011, http://ecdc.europa.eu/en/publications/Publications/TER_100914_Hep_B_C%20_EU_neighbourhood.pdf, World Health Organization.
7. Plotkin O. Vaccine 2008, Amsterdam: Saunders Elsevier.
8. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005, 142:821-831. 10.7326/0003-4819-142-10-200505170-00007, 15897532.
9. Takeda A, Jones J, Shepherd J, Davidson P, Price A. A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B. J Viral Hepat 2007, 14:75-88. 10.1111/j.1365-2893.2006.00808.x, 17244247.
10. Shepherd J, Brodin HF, Cave CB, Waugh NR, Price A, Gabbay J. Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Int J Technol Assess Health Care 2005, 21:47-54.
11. European Association For The Study Of The Liver EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009, 50:227-242. European Association For The Study Of The Liver.
12. European Association For The Study Of The Liver EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55:245-264. European Association For The Study Of The Liver.
13. Martin NK, Vickerman P, Hickman M. Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol 2011, 274:58-66. 10.1016/j.jtbi.2010.12.041, 21236265.
14. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011, 54:1137-1144. 10.1016/j.jhep.2010.08.029, 21145810.
15. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011, 365:493-505. 10.1056/NEJMoa1105243, 3200068, 21767103.
16. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127:S35-S50. 10.1053/j.gastro.2004.09.014, 15508101.
17. Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008, 134:1699-1714. 10.1053/j.gastro.2008.02.069, 18471548.
18. Wasley A, Finelli L, Bell B, Alter M. The knowledge and behaviors of HCV-infected persons identified in a seroprevalence survey, USA, 2001-2002 [abstract]. J Clin Virol 2006, 36:S198-S199.
19. Richter C, Beest GT, Sancak I, Aydinly R, Bulbul K, Laetemia-Tomata F, DE Leeuw M, Waegemaekers T, Swanink C, Roovers E. Hepatitis B prevalence in the Turkish population of Arnhem: implications for national screening policy?. Epidemiol Infect 2012, 140:724-730. 10.1017/S0950268811001270, 21740610.
20. Kwiatkowski CF, Fortuin CK, Booth RE. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction 2002, 97:1289-1294. 10.1046/j.1360-0443.2002.00208.x, 12359033.
21. Culver DH, Alter MJ, Mullan RJ, Margolis HS. Evaluation of the effectiveness of targeted lookback for HCV infection in the United States-interim results. Transfusion 2000, 40:1176-1181. 10.1046/j.1537-2995.2000.40101176.x, 11061852.
22. Hagan H, Campbell J, Thiede H, Strathdee S, Ouellet L, Kapadia F, Hudson S, Garfein RS. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep 2006, 121:710-719. 1781913, 17278406.
23. Hutchinson SJ, Roy KM, Wadd S, Bird SM, Taylor A, Anderson E, Shaw L, Codere G, Goldberg DJ. Hepatitis C virus infection in Scotland: epidemiological review and public health challenges. Scott Med J 2006, 51:8-15.
24. Meffre C, Le Strat Y, Delarocque-Astagneau E, Dubois F, Antona D, Lemasson JM, Warszawski J, Steinmetz J, Coste D, Meyer JF, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol 2010, 82:546-555. 10.1002/jmv.21734, 20166185.
25. Hahné SJ, de Melker HE, Kretzschmar M, Mollema L, vd Klis FR, vd Sande MA, Boot HJ. Prevalence of hepatitis B virus infection in The Netherlands in 1996 and 2007. Epidemiol Infect 2012, 140:1469-1480. 10.1017/S095026881100224X, 22078095.
26. European Centre for Disease Prevention and Control Surveillance and prevention of hepatitis B and C in Europe 2010, Stockholm, http://www.edqm.eu/medias/fichiers/The_Collection_Testing_and_Use_of_Blood_and_Blood_.pdf, European Centre for Disease Prevention and Control.
27. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004, 38:S158-S168.
28. Muhlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Publ Health 2009, 9:34.
29. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008, 48:148-162. 10.1016/j.jhep.2007.07.033, 18022726.
30. Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Muhlberger N, Wright D, Zeuzem S, Siebert U. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. Eur J Publ Health 2009, 19:245-253.
31. van der Poel C, Janssen MP, Borkent-Raven B. The collection, testing and use of blood and blood products in Europe in 2005, http://www.edqm.eu/medias/fichiers/The_Collection_Testing_and_Use_of_Blood_and_Blood_pdf.
32. European Monitoring Centre for Drugs and Drugs Addiction (EMCDDA) Drug related infectious diseases 2010, Statistical Bulletin, http://www.emcdda.europa.eu/stats10, European Monitoring Centre for Drugs and Drugs Addiction (EMCDDA).
33. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011, 378:571-583. 10.1016/S0140-6736(11)61097-0, 3285467, 21802134.
34. OECD Purchasing Power Parities (PPPs) 2012, Available from http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&language=en&pcode=tec00118&tableSelection=1&footnotes=yes&labeling=labels&plugin=1. Accessed 13 April 2012, OECD.
35. Eurostat Inflation rates 2012, Available from http://appsso.eurostat.ec.europa.eu/nui/show.do. Accessed 2 March 2012, Eurostat.
36. Eurostat Population size by country 2009, Available from http://epp.eurostat.ec.europa.eu/portal/page/portal/statistics/search_database. Accessed 22 July 2009, Eurostat.
37. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009, 6:e1000100. 10.1371/journal.pmed.1000100, 2707010, 19621070.
38. Roy KM, Goldberg DJ, Wilson K, Cameron SO. Vaccination induced immunity to the hepatitis B virus among high-risk groups in Glasgow 1993-2001: evaluating the effectiveness of the United Kingdom's selective immunisation policy. Scott Med J 2008, 53:13-17.
39. McMillan A. The changing prevalence of hepatitis B virus infection among men who have sex with men who attended a sexually transmitted infections clinic in Edinburgh, Scotland between 1989 and 2003. Int J STD AIDS 2006, 17:539-542. 10.1258/095646206778145613, 16925901.
40. Christiansen MA, Lowhagen GB. Sexually transmitted diseases and sexual behavior in men attending an outpatients' clinic for gay men in Gothenburg, Sweden. Acta Derm Venereol 2000, 80:136-139.
41. Baaten GG, Sonder GJ, Dukers NH, Coutinho RA, van den Hoek JA. Population-based study on the seroprevalence of hepatitis A, B, and C virus infection in Amsterdam, 2004. J Med Virol 2007, 79:1802-1810. 10.1002/jmv.21009, 17935187.
42. Cavlek TV, Margan IG, Lepej SZ, Kolaric B, Vince A. Seroprevalence, risk factors, and hepatitis C virus genotypes in groups with high-risk sexual behavior in Croatia. J Med Virol 2009, 81:1348-1353. 10.1002/jmv.21530, 19551819.
43. Kerr RS, Fernando I, Templeton K, Flynn B. Hepatitis C screening in genitourinary clinic attendees. Int J STD AIDS 2009, 20:808.
44. Stein K, Dalziel K, Walker A, Jenkins B, Round A, Royle P. Screening for Hepatitis C in injecting drug users: a cost utility analysis. J Public Health (Oxf) 2004, 26:61-71.
45. Stein K, Dalziel K, Walker A, Jenkins B, Round A, Royle P. Screening for hepatitis C in genito-urinary medicine clinics: a cost utility analysis. J Hepatol 2003, 39:814-825. 10.1016/S0168-8278(03)00392-1, 14568266.
46. Stein K, Dalziel K, Walker A, McIntyre L, Jenkins B, Horne J, Royle P, Round A. Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice. Health Technol Assess 2002, 6:1-122.
47. Eckman MH, Kaiser TE, Sherman KE. The cost-effectiveness of screening for chronic hepatitis B infection in the United States. Clin Infect Dis 2011, 52:1294-1306. 10.1093/cid/cir199, 3097367, 21540206.
48. Loubiere S, Rotily M, Moatti JP. Prevention could be less cost-effective than cure: the case of hepatitis C screening policies in France. Int J Technol Assess Health Care 2003, 19:632-645.
49. Singer ME, Younossi ZM. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med 2001, 111:614-621. 10.1016/S0002-9343(01)00951-2, 11755504.
50. Nakamura J, Terajima K, Aoyagi Y, Akazawa K. Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups. Tohoku J Exp Med 2008, 215:33-42. 10.1620/tjem.215.33, 18509233.
51. Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis 2012, 54:1259-1271. 10.1093/cid/cis011, 3404694, 22412061.
52. McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, Capretta JC, O'Grady MJ, Weinstein MC. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology 2012, 55:1344-1355. 10.1002/hep.25510, 22135116.
53. Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, Patel N, Ward JW, Weinbaum CM. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012, 156:263-270. 10.7326/0003-4819-156-4-201202210-00378, 22056542.
54. Tormans G, Van Damme P, Carrin G, Clara R, Eylenbosch W. Cost-effectiveness analysis of prenatal screening and vaccination of hepatitis B virus - the case of Belgium. Soc Sci Med 1993, 37:173-181. 10.1016/0277-9536(93)90453-B, 8351532.
55. Jordan R, Law M. An appraisal of the efficacy and cost-effectiveness of antenatal screening for hepatitis B. J Med Screen 1997, 4:117-127.
56. Dwyer MJ, McIntyre PG. Ante-natal screening for hepatitis B surface antigen: an appraisal of its value in a low prevalence area. Epidemiol Infect 1996, 117:121-131. 10.1017/S0950268800001217, 2271686, 8760959.
57. Audet AM, Delage G, Remis RS. Screening for HBsAg in pregnant women: a cost analysis of the universal screening policy in the province of Quebec. Can J Publ Health 1991, 82:191-195.
58. Thomas IL. Cost effectiveness of antenatal hepatitis B screening and vaccination of infants. Aust N Z J Obstet Gynaecol 1990, 30:331-335. 10.1111/j.1479-828X.1990.tb02022.x, 2150586.
59. Plunkett BA, Grobman WA. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis. Am J Obstet Gynecol 2005, 192:1153-1161. 10.1016/j.ajog.2004.10.600, 15846195.
60. Leal P, Stein K, Rosenberg W. What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users?. J Med Screen 1999, 6:124-131. 10.1136/jms.6.3.124, 10572842.
61. Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A, Stein K. The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technol Assess 2006, 10:iii-xii. 1.
62. Thompson CJ, Castelnuovo E, Pitt M, Cramp M, Siebert U, Stein K. Case finding for hepatitis C in primary care: a cost utility analysis. Fam Pract 2006, 23:393-406. 10.1093/fampra/cml032, 16799165.
63. Josset V, Torre JP, Tavolacci MP, Rossem-Magnani V, Anselme K, Merle V, Godart J, Libert A, Ladner J, Czernichow P. Efficiency of hepatitis C virus screening strategies in general practice.[see comment]. Gastroenterol Clin Biol 2004, 28:351-357. 10.1016/S0399-8320(04)94935-4, 15146150.
64. Honeycutt AA, Harris JL, Khavjou O, Buffington J, Jones TS, Rein DB. The costs and impacts of testing for hepatitis C virus antibody in public STD clinics. Publ Health Rep 2007, 122(Suppl 2):55-62.
65. Tramarin A, Gennaro N, Compostella FA, Gallo C, Wendelaar Bonga LJ, Postma MJ. HCV screening to enable early treatment of hepatitis C: a mathematical model to analyse costs and outcomes in two populations. Curr Pharm Des 2008, 14:1655-1660. 10.2174/138161208784746833, 18673188.
66. Helsper CW, Borkent-Raven BA, DE Wit NJ, VAN Essen GA, Bonten MJ, Hoepelman AI, Janssen MP, De Wit GA. Cost-effectiveness of targeted screening for hepatitis C in The Netherlands. Epidemiol Infect 2012, 140:58-69. 10.1017/S0950268811000112, 21324216.
67. Hutton DW, Tan D, So SK, Brandeau ML. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med 2007, 147:460-469. 10.7326/0003-4819-147-7-200710020-00004, 17909207.
68. Veldhuijzen IK, Toy M, Hahne SJ, De Wit GA, Schalm SW, de Man RA, Richardus JH. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Gastroenterology 2010, 138:522-530. 10.1053/j.gastro.2009.10.039, 19879275.
69. Rein DB, Lesesne SB, Smith BD, Weinbaum CM. Models of community-based hepatitis B surface antigen screening programs in the U.S. and their estimated outcomes and costs. Publ Health Rep 2011, 126:560-567.
70. Wong WW, Woo G, Jenny HE, Krahn M. Cost effectiveness of screening immigrants for hepatitis B. Liver Int 2011, 31:1179-1190. 10.1111/j.1478-3231.2011.02559.x, 21745300.
71. Sutton AJ, Edmunds WJ, Gill ON. Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison. BMC Publ Health 2006, 6:170.
72. Sutton AJ, Edmunds WJ, Sweeting MJ, Gill ON. The cost-effectiveness of screening and treatment for hepatitis C in prisons in England and Wales: a cost-utility analysis. J Viral Hepat 2008, 15:797-808.
73. Ruggeri M, Cicchetti A, Gasbarrini A. The cost-effectiveness of alternative strategies against HBV in Italy. Health Policy 2011, 102:72-80. 10.1016/j.healthpol.2010.09.012, 21035229.
74. Fabris P, Baldo V, Baldovin T, Bellotto E, Rassu M, Trivello R, Tramarin A, Tositti G, Floreani A. Changing epidemiology of HCV and HBV infections in Northern Italy: a survey in the general population. J Clin Gastroenterol 2008, 42:527-532. 10.1097/MCG.0b013e318030e3ab, 18277889.
75. Toy M, Onder FO, Wormann T, Bozdayi AM, Schalm SW, Borsboom GJ, van Rosmalen J, Richardus JH, Yurdaydin C. Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review. BMC Infect Dis 2011, 11:337. 10.1186/1471-2334-11-337, 3262158, 22151620.
76. Ferraro D, Genovese D, Argentini C, Giordano V, Pizzillo P, Stroffolini T, Craxi A, Rapicetta M, Di Stefano R. Phylogenetic reconstruction of HCV genotype 1b dissemination in a small city centre: the Camporeale model. J Med Virol 2008, 80:1723-1731. 10.1002/jmv.21276, 18712845.
77. Rossi C, Shrier I, Marshall L, Cnossen S, Schwartzman K, Klein MB, Schwarzer G, Greenaway C. Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees: a systematic review and meta-analysis. PLoS One 2012, 7:e44611. 10.1371/journal.pone.0044611, 3434171, 22957088.
78. Anderson EM, Mandeville RP, Hutchinson SJ, Cameron SO, Mills PR, Fox R, Ahmed S, Taylor A, Spence E, Goldberg DJ. Evaluation of a general practice based hepatitis C virus screening intervention. Scott Med J 2009, 54:3-7.
79. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Annual report 2012: the state of the drugs problem in Europe 2012, Luxembourg: Publications Office of the European Union, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
80. Wiessing L, Blystad H. EMCDDA publishes guidelines on testing for HIV, viral hepatitis and other infections in injecting drug users. Euro Surveill 2010, 15(48).
81. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Guidelines for testing HIV, viral hepatitis and other infections in injecting drug users 2010, Lisbon, http://www.emcdda.europa.eu/publications/manuals/testing-guidelines, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
82. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 2006, 332:328-336. 10.1136/bmj.38719.435833.7C, 1363909, 16443611.
83. World Health Organisation Hepatitis B vaccines. Position paper. Weekly Epidemiol Record 2009, 40:405-420. World Health Organisation.
84. Van Der Veen YJ, Van Empelen P, Richardus JH. Development of a culturally tailored Internet intervention promoting hepatitis B screening in the Turkish community in the Netherlands. Health Promot Int 2012, 27:342-355. 10.1093/heapro/dar044, 21795303.
85. Hahné S, Wormann Nee MT, Kretzschmar M. Migrants and hepatitis B: new strategies for secondary prevention needed. Eur J Publ Health 2009, 19:439.
86. Urbanus AT, van de Laar TJ, Vanden HA, Zuure FR, Speksnijder AG, Baaten GG, Heijman T, Vriend HJ, op de Coul EL, Coutinho RA, et al. Hepatitis C in the general population of various ethnic origins living in the Netherlands: Should non-Western migrants be screened?. J Hepatol 2011, 55:1207-1214. 10.1016/j.jhep.2011.02.028, 21703202.
87. CDC Recommendations for the identification of chronic hepatitis c virus infection among persons born during 1945-1965. MMWR Morb Mortal Wkly Rep 2012, 61:1-32. CDC.
88. Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 2012, 55:49-57. 10.1002/hep.24656, 21898506.
89. Walker DG, Hutubessy R, Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine 2010, 28:2356-2359. 10.1016/j.vaccine.2009.06.035, 19567247.
90. Beutels P, Edmunds WJ, Antoñanzas F, De Wit GA, Evans D, Feilden R, Fendrick AM, Ginsberg GM, Glick HA, Mast E, Péchevis M, Van Doorslaer EK, van Hout BA. Viral Hepatitis Prevention Board: Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics 2002, 20:1-7.
91. Quoilin S, Hutse V, Vandenberghe H, Claeys F, Verhaegen E, De Cock L, Van Loock F, Top G, Van Damme P, Vranckx R, et al. A population-based prevalence study of hepatitis A, B and C virus using oral fluid in Flanders, Belgium. Eur J Epidemiol 2007, 22:195-202. 10.1007/s10654-007-9105-6, 17356926.
92. Nemecek V, Castkova J, Fritz P, Linhartova A, Svandova E, Sramova H, Kriz B. The 2001 serological survey in the Czech Republic--viral hepatitis. Cent Eur J Public Health 2003, 11:S54-S61. 10.1007/BF02955965, 15080261.
93. Nardone A, Anastassopoulou CG, Theeten H, Kriz B, Davidkin I, Thierfelder W, O'Flanagan D, Bruzzone B, Mossong J, Boot HJ, et al. A comparison of hepatitis B seroepidemiology in ten European countries. Epidemiol Infect 2009, 137:961-969. 10.1017/S0950268808001672, 19102797.
94. Jilg W, Hottentrager B, Weinberger K, Schlottmann K, Frick E, Holstege A, Scholmerich J, Palitzsch KD. Prevalence of markers of hepatitis B in the adult German population. J Med Virol 2001, 63:96-102. 10.1002/1096-9071(20000201)63:2<96::AID-JMV1002>3.0.CO;2-C, 11170044.
95. Thierfelder W, Hellenbrand W, Meisel H, Schreier E, Dortschy R. Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998. Eur J Epidemiol 2001, 17:429-435. 10.1023/A:1013792013184, 11855576.
96. Gogos CA, Fouka KP, Nikiforidis G, Avgeridis K, Sakellaropoulos G, Bassaris H, Maniatis A, Skoutelis A. Prevalence of hepatitis B and C virus infection in the general population and selected groups in South-Western Greece. Eur J Epidemiol 2003, 18:551-557.
97. Raffaele A, Valenti M, Iovenitti M, Matani A, Bruno ML, Altobelli E, D'Alessandro A, Barnabei R, Leonardis B, Taglieri G. High prevalence of HCV infection among the general population in a rural area of central Italy. Eur J Epidemiol 2001, 17:41-46. 10.1023/A:1010932832190, 11523574.
98. Maio G, d'Argenio P, Stroffolini T, Bozza A, Sacco L, Tosti ME, Intorcia M, Fossi E, d'Alessio G, Kondili LA, et al. Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a southern Italian town. J Hepatol 2000, 33:116-120. 10.1016/S0168-8278(00)80167-1, 10905594.
99. Pendino GM, Mariano A, Surace P, Caserta CA, Fiorillo MT, Amante A, Bruno S, Mangano C, Polito I, Amato F, et al. Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology 2005, 41:1151-1159. 10.1002/hep.20689, 15841464.
100. Coppola RC, Masia G, Pradat P, Trepo C, Carboni G, Argiolas F, Rizzetto M. Impact of hepatitis C virus infection on healthy subjects on an Italian island. J Viral Hepat 2000, 7:130-137. 10.1046/j.1365-2893.2000.00199.x, 10760043.
101. Di Stefano R, Stroffolini T, Ferraro D, Usticano A, Valenza LM, Montalbano L, Pomara G, Craxi A. Endemic hepatitis C virus infection in a Sicilian town: further evidence for iatrogenic transmission. J Med Virol 2002, 67:339-344. 10.1002/jmv.10081, 12116024.
102. Dominguez A, Bruguera M, Vidal J, Plans P, Salleras L. Changes in the seroepidemiology of hepatitis B infection in Catalonia 1989-1996. Vaccine 2000, 18:2345-2350. 10.1016/S0264-410X(00)00028-1, 10738090.
103. Salleras L, Dominguez A, Bruguera M, Plans P, Costa J, Cardenosa N, Batalla J, Plasencia A. Declining prevalence of hepatitis B virus infection in Catalonia (Spain) 12 years after the introduction of universal vaccination. Vaccine 2007, 25:8726-8731. 10.1016/j.vaccine.2007.10.027, 18045753.
104. Hoffmann G, Berglund G, Elmstahl S, Eriksson S, Verbaan H, Widell A, Lindgren S. Prevalence and clinical spectrum of chronic viral hepatitis in a middle-aged Swedish general urban population. Scand J Gastroenterol 2000, 35:861-865.
105. Akcam FZ, Uskun E, Avsar K, Songur Y. Hepatitis B virus and hepatitis C virus seroprevalence in rural areas of the southwestern region of Turkey. Int J Infect Dis 2009, 13:274-284. 10.1016/j.ijid.2008.07.005, 18945630.
106. Demirturk N, Demirdal T, Toprak D, Altindis M, Aktepe OC. Hepatitis B and C virus in West-Central Turkey: seroprevalence in healthy individuals admitted to a university hospital for routine health checks. Turk J Gastroenterol 2006, 17:267-272.
107. Guven R, Ozcebe H, Cakir B. Hepatitis B prevalence among workers in Turkey at low risk for hepatitis B exposure. East Mediterr Health J 2006, 12:749-757.
108. Yildirim B, Barut S, Bulut Y, Yenisehirli G, Ozdemir M, Cetin I, Etikan I, Akbas A, Atis O, Ozyurt H, et al. Seroprevalence of hepatitis B and C viruses in the province of Tokat in the Black Sea region of Turkey: A population-based study. [see comment]. Turk J Gastroenterol 2009, 20:27-30.
109. Degertekin H, Tuzcu A, Yalcin K. Horizontal transmission of HBV infection among students in Turkey. Publ Health 2000, 114:411-412.
110. Mehmet D, Meliksah E, Serif Y, Gunay S, Tuncer O, Zeynep S. Prevalence of hepatitis B infection in the southeastern region of Turkey: comparison of risk factors for HBV infection in rural and urban areas. Jpn J Infect Dis 2005, 58:15-19.
111. Van Damme P, Thyssen A, Van Loock F. Epidemiology of hepatitis C in Belgium: present and future. Acta Gastroenterol Belg 2002, 65:78-79.
112. Atanasova MV, Haydouchka IA, Zlatev SP, Stoilova YD, Iliev YT, Mateva NG. Prevalence of antibodies against hepatitis C virus and hepatitis B coinfection in healthy population in Bulgaria. A seroepidemiological study. Minerva Gastroenterol Dietol 2004, 50:89-96.
113. Pradat P, Caillat-Vallet E, Sahajian F, Bailly F, Excler G, Sepetjan M, Trepo C, Fabry J, members A Prevalence of hepatitis C infection among general practice patients in the Lyon area, France. Eur J Epidemiol 2001, 17:47-51. 10.1023/A:1010902614443, 11523575, members A.
114. Goritsas C, Plerou I, Agaliotis S, Spinthaki R, Mimidis K, Velissaris D, Lazarou N, Labropoulou-Karatza C. HCV infection in the general population of a Greek island: prevalence and risk factors. Hepatogastroenterology 2000, 47:782-785.
115. Campello C, Poli A, Dal MG, Besozzi-Valentini F. Seroprevalence, viremia and genotype distribution of hepatitis C virus: a community-based population study in northern Italy. Infection 2002, 30:7-12. 10.1007/s15010-001-1197-4, 11876521.
116. Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection.[summary for patients in Ann Intern Med. 2002 Dec 17;137(12):I36; PMID: 12484740]. Ann Intern Med 2002, 137:961-964. 10.7326/0003-4819-137-12-200212170-00009, 12484711.
117. Petti S, Divizia M, Donia D, D' Arca AS, Tarsitani G, Fabi G, Pana A. Analysis of the shift of the transmission pattern for hepatitis C in a community in Central Italy. New Microbiol 2006, 29:207-209.
118. Montella M, Crispo A, Grimaldi M, Angeletti C, Amore A, Ronga D, Sabbatini M, Pisani A, Spiteri D, Serraino D. Prevalence of hepatitis C virus infection in different population groups in southern Italy.[erratum appears in Infection. 2005 Apr;33(2):103 Note: Sabbatici, M [corrected to Sabbatini, M]]. Infection 2005, 33:9-12. 10.1007/s15010-005-4036-1, 15750753.
119. Slavenburg S, Verduyn-Lunel FM, Hermsen JT, Melchers WJG, te Morsche RHM, Drenth JPH. Prevalence of hepatitis C in the general population in the Netherlands. Neth J Med 2008, 66:13-17.
120. Bielawski K, Wlasiuk M, Truskolawska M, Falkiewicz B. HCV infection in Poland. Arch Med Res 2000, 31:532-535. 10.1016/S0188-4409(00)00100-4, 11179591.
121. Gheorghe L, Iacob S, Csiki IE. Prevalence of hepatitis C in Romania: different from European rates?. J Hepatol 2008, 49:661-662. 10.1016/j.jhep.2008.06.016, 18684541.
122. Dominguez A, Bruguera M, Vidal J, Plans P, Salleras L. Community-based seroepidemiological survey of HCV infection in Catalonia, Spain. J Med Virol 2001, 65:688-693. 10.1002/jmv.2091, 11745932.
123. Riestra S, Fernandez E, Leiva P, Garcia S, Ocio G, Rodrigo L. Prevalence of hepatitis C virus infection in the general population of northern Spain.[see comment]. Eur J Gastroenterol Hepatol 2001, 13:477-481. 10.1097/00042737-200105000-00003, 11396524.
124. Balogun MA, Ramsay ME, Hesketh LM, Andrews N, Osborne KP, Gay NJ, Morgan-Capner P. The prevalence of hepatitis C in England and Wales. J Infect 2002, 45:219-226. 10.1053/jinf.2002.1059, 12423608.
125. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6:e1000097. 10.1371/journal.pmed.1000097, 2707599, 19621072.
126. Altindis M, Yilmaz S, Dikengil T, Acemoglu H, Hosoglu S. Seroprevalence and genotyping of hepatitis B, hepatitis C and HIV among healthy population and Turkish soldiers in Northern Cyprus. World J Gastroenterol 2006, 12:6792-6.
127. Offergeld R, Faensen D, Ritter S, Hamouda O. Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: risk of virus transmission and the impact of nucleic acid amplification testing. Euro Surveill 2005, 10:8-11.
128. Zervou EK, Dalekos GN, Boumba DS, Tsianos EV. Value of anti-HBc screening of blood donors for prevention of HBV infection: results of a 3-year prospective study in Northwestern Greece. Transfusion 2001, 41:652-8. 10.1046/j.1537-2995.2001.41050652.x, 11346702.
129. Manzini P, Girotto M, Borsotti R, Giachino O, Guaschino R, Lanteri M, et al. Italian blood donors with anti-HBc and occult hepatitis B virus infection. Haematologica 2007, 92:1664-70. 10.3324/haematol.11224, 18055990.
130. Kalibatas V. Payment for whole blood donations in Lithuania: the risk for infectious disease markers.[see comment]. Vox Sang 2008, 94:209-15. 10.1111/j.1423-0410.2007.01015.x, 18069929.
131. Chlabicz S, Bonifatiuk I, Radziwon P. Prevalence of hepatitis C virus antibodies among blood donors in north-eastern Poland. Hepatol 2005, 33:206-10.
132. Eiras A, Sauleda S, Planelles D, Sedeno M, Ibarra A, Vesga MA, et al. HCV screening in blood donations using RT-PCR in mini-pool: the experience in Spain after routine use for 2 years. Transfusion 2003, 43:713-20. 10.1046/j.1537-2995.2003.00420.x, 12757521.
133. Cowan SA, Bagdonaite J, Qureshi K. Universal hepatitis B screening of pregnant women in Denmark ascertains substantial additional infections: results from the first five months. Euro Surveill 2006, 11:E060608.
134. Denis F, Ranger-Rogez S, Alain S, Mounier M, Debrock C, Wagner A, et al. Screening of pregnant women for hepatitis B markers in a French Provincial University Hospital (Limoges) during 15 years. Eur J Epidemiol 2004, 19:973-8. 10.1007/s10654-004-5755-9, 15575357.
135. Knorr B, Maul H, Schnitzler P. Prevalence of hepatitis B virus infection among women at reproductive age at a German university hospital. J Clin Virol 2008, 42:422-4. 10.1016/j.jcv.2008.03.009, 18448387.
136. Papaevangelou V, Hadjichristodoulou C, Cassimos D, Theodoridou M. Adherence to the screening programme for HBV infection in pregnant women delivering in Greece. BMC Infect Dis 2006, 6:84. 10.1186/1471-2334-6-84, 1475591, 16681862.
137. Healy CM, Cafferkey MT, Butler KM, Cahill I, McMorrow J, Philbin M, et al. Antenatal hepatitis B screening - is there a need for a national policy?. Ir Med J 2001, 94:111-2.
138. Stroffolini T, Bianco E, Szklo A, Bernacchia R, Bove C, Colucci M, et al. Factors affecting the compliance of the antenatal hepatitis B screening programme in Italy. Vaccine 2003, 21:1246-9. 10.1016/S0264-410X(02)00439-5, 12559805.
139. van Steenbergen JE, Leentvaar-Kuijpers A, Baayen D, Dukers HT, van Doornum GJ, van den Hoek JA, et al. Evaluation of the hepatitis B antenatal screening and neonatal immunization programme in Amsterdam, 1993-1998. Vaccine 2001, 12:7-11.
140. Stanekova D, Adamcakova J, Kopilcova T, Kotuliak J, Vaculikova E, Habekova M, et al. Serological markers of selected sexually and blood transmitted infections in pregnant women and in newborns of HIV-positive mothers in the Slovak Republic. Cent Eur J Publ Health 2006, 14:104-8.
141. Salleras L, Dominguez A, Bruguera M, Plans P, Espunes J, Costa J, et al. Seroepidemiology of hepatitis B virus infection in pregnant women in Catalonia (Spain). J Clin Virol 2009, 44:329-32. 10.1016/j.jcv.2009.01.002, 19230752.
142. Beckers K, Schaad UB, Heininger U. Compliance with antenatal screening for hepatitis B surface antigen carrier status in pregnant women and consecutive procedures in exposed newborns. Eur J Pediatr 2004, 163:654-7.
143. Anderson SR, Righarts A, Maguire H. Surveillance of antenatal infections-HIV, hepatitis B, syphilis and rubella susceptibility in London. Commun Dis Publ Health 2004, 7:251-7.
144. Hillemanns P, Dannecker C, Kimmig R, Hasbargen U. Obstetric risks and vertical transmission of hepatitis C virus infection in pregnancy. Acta Obstet Gynecol Scand 2000, 79:543-7. 10.1080/j.1600-0412.2000.079007543.x, 10929952.
145. Panagopoulos P, Economou A, Kasimi A, Spyropoulou P, Kanellopoulos N, Dadiotis L, et al. Prevalence of hepatitis B and C in the maternity department of a Greek district hospital. J Matern Fetal Neonatal Med 2004, 16:106-10.
146. Raptopoulou-Gigi M, Orphanou E, Lalla TH, Lita A, Garifallos A. Prevalence of hepatitis C virus infection in a cohort of pregnant women in northern Greece and transmission of HCV from mother to child. Eur J Epidemiol 2001, 17:263-6. 10.1023/A:1017951605272, 11680545.
147. Baldo V, Floreani A, Menegon T, Grella P, Paternoster DM, Trivello R. Hepatitis C virus, hepatitis B virus and human immunodeficiency virus infection in pregnant women in North-East Italy: a seroepidemiological study. Eur J Epidemiol 2000, 16:87-91. 10.1023/A:1007600532105, 10780348.
148. Conte D, Fraquelli M, Prati D, Colucci A, Minola E. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 2000, 31:751-5. 10.1002/hep.510310328, 10706568.
149. Veronesi L, Verrotti Di Pianella C, Benassi L, Benaglia G, Affanni P, Tanzi ML. Mother to child transmission of hepatitis C virus in a province of northern Italy. J Prev Med Hyg 2007, 48:47-9.
150. Prasad LR, Massery Spicher V, Kammerlander R, Zwahlen M. Hepatitis C in a sample of pregnant women in Switzerland: seroprevalence and socio-demographic factors. Swiss Med Wkly 2007, 137:27-32.
151. Ades AE, Parker S, Walker J, Cubitt WD, Jones R. HCV prevalence in pregnant women in the UK. Epidemiol Infect 2000, 125:399-405. 10.1017/S0950268899004598, 2869613, 11117964.
152. Balogun MA, Ramsay ME, Parry JV, Donovan L, Andrews NJ, Newham JA, et al. The prevalence and genetic diversity of hepatitis C infection in antenatal clinic attenders in two regions of England. Epidemiol Infect 2000, 125:705-12. 10.1017/S0950268800004696, 2869654, 11218221.
153. Ward C, Tudor-Williams G, Cotzias T, Hargreaves S, Regan L, Foster GR. Prevalence of hepatitis C among pregnant women attending an inner London obstetric department: uptake and acceptability of named antenatal testing.[see comment]. Gut 2000, 47:277-80. 10.1136/gut.47.2.277, 1728010, 10896922.
154. Goldberg D, McIntyre PG, Smith R, Appleyard K, Dunlop J, Taylor A, et al. Hepatitis C virus among high and low risk pregnant women in Dundee: unlinked anonymous testing. Br J Obstet Gyn 2001, 108:365-70.
155. Hutchinson SJ, Goldberg DJ, King M, Cameron SO, Shaw LE, Brown A, et al. Hepatitis C virus among childbearing women in Scotland: prevalence, deprivation, and diagnosis. Gut 2004, 53:593-8. 10.1136/gut.2003.027383, 1774001, 15016757.
156. Roussos A, Goritsas C, Pappas T, Spanaki M, Papadaki P, Ferti A. Prevalence of hepatitis B and C markers among refugees in Athens. World J Gastroenterol 2003, 9:993-5.
157. Chironna M, Germinario C, Lopalco PL, Quarto M, Barbuti S. HBV, HCV and HDV infections in Albanian refugees in Southern Italy (Apulia region). Epidemiol Infect 2000, 125:163-7. 10.1017/S0950268899004215, 2869582, 11057972.
158. Palumbo E, Scotto G, Faleo G, Cibelli DC, Angarano G. Prevalence of HBV genotypes in South American immigrants affected by HBV-related chronic active hepatitis. Braz J Infect Dis 2007, 11:311-3. 10.1590/S1413-86702007000300002, 17684630.
159. Palumbo E, Scotto G, Faleo G, Cibelli DC, Saracino A, Angarano G. Prevalence of HBV-genotypes in immigrants affected by HBV-related chronic active hepatitis. Arq Gastroenterol 2007, 44:54-7.
160. Majori S, Baldo V, Tommasi I, Malizia M, Floreani A, Monteiro G, et al. Hepatitis A, B, and C infection in a community of sub-Saharan immigrants living in Verona (Italy). J Travel Med 2008, 15:323-7. 10.1111/j.1708-8305.2008.00230.x, 19006505.
161. Palumbo E, Scotto G, Cibelli DC, Faleo G, Saracin A, Angarano G. Immigration and hepatitis B virus: epidemiological, clinical and therapeutic aspects. East Mediterr Health J 2008, 14:784-90.
162. Manzardo C, Trevino B, Prat J, Cabezos J, Mongui E, Claveria I, et al. Communicable diseases in the immigrant population attended to in a tropical medicine unit: epidemiological aspects and public health issues. Travel Med Infect Dis 2008, 6:4-11. 10.1016/j.tmaid.2007.11.002, 18342267.
163. Chironna M, Germinario C, Lopalco PL, Carrozzini F, Barbuti S, Quarto M. Prevalence rates of viral hepatitis infections in refugee Kurds from Iraq and Turkey.[see comment]. Infection 2003, 31:70-4. 10.1007/s15010-002-3100-3, 12682810.
164. Aweis D, Brabin B, Beeching N, Bunn J, Cooper C, Gardner K, et al. Hepatitis B prevalence and risk factors for HBsAg carriage amongst Somali households in Liverpool. Commun Dis Publ Health 2001, 4:247-52.
165. Michos A, Terzidis A, Kalampoki V, Pantelakis K, Spanos T, Petridou ET. Seroprevalence and risk factors for hepatitis A, B, and C among Roma and non-Roma children in a deprived area of Athens, Greece. J Med Virol 2008, 80:791-7. 10.1002/jmv.21134, 18360892.
166. Chironna M, Germinario C, Lopalco PL, Carrozzini F, Quarto M. Prevalence of hepatitis virus infections in Kosovar refugees. Int J Infect Dis 2001, 5:209-13. 10.1016/S1201-9712(01)90073-6, 11953219.
167. Veldhuijzen IK, van Driel HF, Vos D, de ZO, van Doornum GJ, de Man RA, et al. Viral hepatitis in a multi-ethnic neighborhood in the Netherlands: results of a community-based study in a low prevalence country. Int J Infect Dis 2009, 13:e9-e13. 10.1016/j.ijid.2008.05.1224, 18678518.
168. Gyarmathy VA, Ujhelyi E, Neaigus A. HIV and selected blood-borne and sexually transmitted infections in a predominantly Roma (Gypsy) neighbourhood in Budapest, Hungary: a rapid assessment. Cent Eur J Publ Health 2008, 16:124-7.
169. Viviano E, Vitale F, Perna AM, Cataldo F, Firenze A, Romano N. Human herpesvirus 8 seroprevalence among internationally adopted children coming from Eastern Europe. New Microbiol 2009, 32:11-5.